Clinical trials: Patients With Major Depressive Disorder
Major Depressive Disorder
Computerized Cognitive Behavior Therapy in Treating Depression in Patients With Cancer
This randomized clinical trial studies how well a computerized cognitive behavior therapy program works in treating depression in patients with cancer.
- Trial name
- NCT02837887
- Testing
- Computerized Cognitive Behavior Therapy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Major Depressive Disorder
Efficacy of Pythagorean Self-Awareness Intervention for Major Depressive Disorder
The present study explored the effects of the implementation of the Pythagorean Self Awarenes Intervention (PSAI) on patients diagnosed with major depressive disorder.
- Trial name
- NCT04536714
- Testing
- Pythagorean Self-Awareness Intervention program
- Where
- Greece
- Volunteers
- 69 people
- Sponsor
- Evgenia E. Psarraki
Major Depressive Disorder
Enhancing Psychotherapy for Mood Disorders With Whole Body Hyperthermia
According to the 2005 National Comorbidity Survey-Replication study, approximately 20.9 million American adults, or 9.5 percent of the population over the age of 18 suffer from mood disorders including major depressive disorder…
- Trial name
- NCT02021149
- Testing
- High intensity whole-body infrared heating, Psychotherapy, Questionnaires
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Charles (Chuck) Raison
Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation
Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst Stimulation in Patients With Treatment-Resistant Depression
In recent years, research on the effectiveness of transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (RTD) has been steadily increasing.
- Conditions
- Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation, Accelerated Protocol, Intermittent Theta Burst Stimulation
- Trial name
- NCT07264452
- Testing
- Transcranial Magnetic Stimulation with figure-eight coil
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Major Depressive Disorder
The Antidepressant Advisor (Study 3): fMRI Study to Predict Treatment Response in Patients With Depression
This prospective observational study (ADeSS-Study3) investigates candidate biomarkers prospectively predicting response to antidepressant medications and prognosis in major depressive disorder (MDD).
- Trial name
- ADeSS_S3 (NCT04342299)
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- King's College London
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
- Trial name
- ORION (NCT00252356)
- Testing
- SR58611A
- Where
- 2 sites in United States, Canada
- Volunteers
- 468 people
- Sponsor
- Sanofi
Major Depressive Disorder
Major Depressive Disorder - Understanding The Link Between The Brain And The Heart
There is strong evidence that patients with major depressive disorder (MDD) have an increased risk of developing coronary heart disease (CHD).
- Trial name
- MDD (NCT01568307)
- Testing
- Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
- Where
- 4 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Baker Heart and Diabetes Institute
Depressive Disorder, Major
Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA)
Tricyclic Antidepressants (TCA's) are the cornerstone of treatment for patients with severe Major Depressive Disorder (sMDD). Current dosing is guided by repeated measurements of blood levels.
- Trial name
- PITA (NCT03548675)
- Testing
- TCA treatment
- Where
- Netherlands
- Volunteers
- 125 people
- Sponsor
- Radboud University Medical Center
Depression
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
- Trial name
- NCT07485595
- Testing
- JS1-1-01 low-dose group, JS1-1-01 high-dose group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Depressive Disorder, Major
A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.
- Trial name
- NCT03352453
- Testing
- Rapastinel
- Where
- 17 sites in United States
- Volunteers
- 138 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of ONO-2333Ms in patients with Recurrent Major Depressive Disorder
- Trial name
- NCT00514865
- Testing
- ONO-2333Ms Experimental 2, ONO-2333Ms Experimental 1
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Ono Pharma USA Inc
Depression
A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
- Trial name
- NCT06259526
- Testing
- JS1-1-01 low-dose group, JS1-1-01 high-dose group, Active drug group
- Where
- 17 sites in China
- Volunteers
- 267 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Major Depressive Disorder
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder (MDD) is a severe and common psychiatric disorder. Although MDD primarily involves mood disturbances, patients also usually present alterations in cognitive function (attention, memory, executive…
- Trial name
- FOCUS (NCT01422213)
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 598 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
Repetitive Transcranial Magnetic Stimulation in Pharmaco-naïve Patients With Major Depression
Repetitive transcranial magnetic stimulation (rTMS) has become a safe and efficacious treatment for patients with treatment-resistant depression.
- Trial name
- NAIV (NCT04000022)
- Testing
- intermittent theta burst stimulation (iTBS)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital, Bonn
Major Depressive Disorder
Long-term Study With Trazodone Once-a-Day
The aim of the present observational study is to assess the clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated an initial positive response to the acute…
- Trial name
- NCT04295941
- Testing
- TraZODone Hydrochloride 300 MG
- Where
- Bulgaria
- Volunteers
- 200 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Anorexia Nervosa
Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Anorexia Nervosa.
In patients suffering from anorexia nervosa associated with severe major depression, serotonin reuptake inhibitor drugs have shown little efficacy in significantly reducing depressive symptoms.
- Trial name
- ANCITA (NCT05795283)
- Testing
- Citalopram i.v. and p.o, Citalopram p.o
- Where
- Italy
- Volunteers
- 123 people
- Sponsor
- Istituto Auxologico Italiano
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression
- Trial name
- NCT00034983
- Testing
- aprepitant, Comparator: paroxetine HCL
- Volunteers
- 900 people
- Sponsor
- Merck Sharp & Dohme LLC
Depressive Disorder, Major
A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant
The purpose of this study is to assess the safety (adverse events, serious adverse events, deaths, suicidality) of participants with major depressive disorder (MDD) treated according to the standard of care (SOC).
- Trial name
- NCT05109195
- Testing
- Standard of Care (SOC)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC